RDPT.F Stock Overview
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Radiopharm Theranostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0008 |
| 52 Week High | AU$0.09 |
| 52 Week Low | AU$0.0008 |
| Beta | 0.92 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| RDPT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 2.7% |
| 1Y | n/a | 3.4% | 26.0% |
Return vs Industry: Insufficient data to determine how RDPT.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RDPT.F performed against the US Market.
Price Volatility
| RDPT.F volatility | |
|---|---|
| RDPT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RDPT.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RDPT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Riccardo Canevari | www.radiopharmtheranostics.com |
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
Radiopharm Theranostics Limited Fundamentals Summary
| RDPT.F fundamental statistics | |
|---|---|
| Market cap | US$11.29m |
| Earnings (TTM) | -US$30.80m |
| Revenue (TTM) | US$3.96m |
2.9x
P/S Ratio-0.4x
P/E RatioIs RDPT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDPT.F income statement (TTM) | |
|---|---|
| Revenue | AU$6.01m |
| Cost of Revenue | AU$26.17m |
| Gross Profit | -AU$20.16m |
| Other Expenses | AU$26.66m |
| Earnings | -AU$46.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | -335.29% |
| Net Profit Margin | -778.57% |
| Debt/Equity Ratio | 0% |
How did RDPT.F perform over the long term?
See historical performance and comparison